Phaseline

Targets › TREML1

TREML1 (Trem-like transcript 1 protein): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Hematology; next expected readout Nov 2027.

Cell surface receptor that may play a role in the innate and adaptive immune response. (UniProt, Q86YW5)

Open in Phaseline: the race on TREML1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Hemab ApSSutacimig
Bispecific antibody binding activated factor VII and TLT-1 on platelets
F7, TREML1Phase 2Congenital Factor VII DeficiencyNov 2027

Conditions

Congenital Factor VII Deficiency (1)

Modalities

antibody (1)

Companies

Hemab ApS (1)

Related targets

F7 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.